What You Should Know: - UPMC today announced the launch of Novasenta, a drug discovery and development company seeking novel and effective treatments for cancer. Co-founded in late 2018 by Robert Ferris, M.D., Ph.D., Dario Vignali, Ph.D., and Greg Delgoffe, Ph.D., all of the UPMC Hillman Cancer Center and Pitt, Novasenta is currently focused on T-cell targets and rapidly advancing programs with the goal of launching its first clinical trial by the end of 2023. - Based on years
Read More
Cancer Drug Approval
AdoRx Therapeutics, J&J Team Up to Develop Novel Lung Cancer Therapeutics
AdoRx Therapeutics, a UK based drug discovery company, and Johnson & Johnson are teaming up to develop novel therapeutics for the treatment of lung cancer. As part of the strategic collaboration, AdoRx has granted an exclusive option to research, develop and commercialize novel antagonists within the AdoRx portfolio, and the groups will collaborate on drug discovery and preclinical development activities. AdoRx Therapeutics is pursuing the discovery of new therapeutics for cancer-based on
Read More
ICON Acquires Precision Medicine for Oncology Company MolecularMD
ICON, a global provider of drug development solutions and services has acquired MolecularMD, a molecular diagnostic specialty laboratory that enables the development and commercialization of precision medicines in oncology. The acquisition of MolecularMD’s extensive scientific and clinical biomarker experience expands the ICON’s capabilities in molecular diagnostic testing and also adds expanded testing platforms, including next-generation sequencing and immunohistochemistry, to ICON’s
Read More
Biotech Startup Lantern Pharma Raises $3.7M to Accelerate Cancer Drug Approval Process
Clinical-stage biotech company Lantern Pharma Inc. has raised $3.7 million in Series A funding led by BIOS Partners, GPG Ventures and other private investors. Using big data and artificial intelligence, Lantern Pharma focused exclusively on accelerating the cancer drug approval process.The startup plans to utilize the funding to continue development of its two lead drug candidates and further the advancement of its big data and Artificial Intelligence (AI) platform. Lantern’s strategy focuses on
Read More
